ArcticZymes Technologies — Investor Presentation 2016

May 19, 2016

Company presentation

May 2016

Svein W. F. Lien – CEO

• This is Biotec Pharmacon
• Q1 Financials
• BetaGlucans
• Advanced wound care

• Enzymes

• Molecular testing
• Outlook

This is Biotec Pharmacon

A corporation of two independent versatile technology platforms

Beta-Glucans:

• Proprietary Beta-Glucans
• Immuno-modulatory substance activating the immune system
• Building up international sales organization in wound care
• Bulk sales of products for Animal Health and Nutrition
• Strong and experienced scientific team with inhouse production

Enzymes - ArcticZymes:

• Unique Cold-adapted Enzymes for the life science industry based on species from the Barents Sea
• International marketing and sales team
• Established relation with core industrial companies (B2B)
• Strong and experienced scientific team with in house production

Biotec is emerging into a commercially driven company

Financial highlights Q1

NOK million	Q1 2016	Q1 2015	12M 2015
Enzymes	8.1	7.6	23.5
BetaGlucans	9.2	4.7	29.7
Sales revenues	17.3	12.3	53.3
EBITDA	-3.5	-2.8	-14.4
EBIT	-4.0	-3.5	-17.3

NOK million	Q1 2016	Q1 2015	12M 2015
Changes in cash and cash equivalent	-10.6	-9.2	-9.9
Cash and cash equivalents at the beginning of period	78.3	88.3	88.3
Cash and cash equivalents at the end of period	67.7	79.1	78.3

Advanced wound care

Beta-Glucan product portfolio

• Animal Health: Deliver feed ingredients to improve animal health in e.g. fish farming
• Nutrition: Deliver bulk ingredients for food supplements
• Cosmetic: Deliver bulk ingredients for cosmetic products
• Medicinal: Produces SBG for use in advanced wound care and for clinical trials as adjuvant in cancer treatment

Vision: "Building a >USD100M Wound Care Company"

Bioactive Beta-Glucan technology demonstrated ability to kick-start "stalled wounds" where healing slowed or stopped:

Positioning for stalled wounds allows Woulgan to show more healing benefit versus standard of care

• Globally >5M stalled wounds ( >60% of all chronic wounds):

UK / Nordic commercial update

UK: Nordic:

US / German update

US:

• Finalizing the "510K application" for Woulgan®
• Expect application to be submitted to the FDA during Q2 2016
• Prepare for partner process

Germany:

Commercialising the Arctic's Uniqueness

Leveraging Uniqueness

Arctic Bioprospecting

• Driven by University of Tromsø (UiT)
• Large biobank of novel enzymes

Discovery

• Identifying commercially attractive & novel enzymes
• Engineering & formulation to enhance desired features

Product Development & Manufacturing

• Cost efficient manufacturing
• Scalability & customisation

Commercialisation

• B2B product offering => Early access
• Support for application development (integration into customer workflows)

Product Portfolio's & Pipeline

Key Elements

• Market Relevance: Focus on most commercial relevant enzymes
• Existing: Extracting maximum value from existing enzymes – new uses in workflows & new formulations
• Pipeline: Regular introduction of new enzymes
• Synergistic Fit: Develop enzymes that can be combined together into customers kits and workflows

OUTLOOK 2016

• Enter into distribution agreement(s) for Woulgan® in Germany
• Finalize the UK reimbursement process in the high-end category of the market
• Full launch and growing revenues in UK and Scandinavia
• Grow business further in Animal Health and Nutrition
• Achieve important milestones in the development of the ArcticZymes business and in the new enzyme development projects

Contact: CFO, Børge Sørvoll bso@biotec.no Tlf: +47 952 90187 www.biotec.no www.woulgan.com

15